Don’t miss the latest developments in business and finance.

Cadila Healthcare rises 5 per cent

Image
BS Reporter Mumbai
Last Updated : Jan 20 2013 | 8:47 PM IST

Cadila Healthcare rose 5.07 per cent to Rs 336.65 after its parent Zydus Cadila received nod to market immuno-suppressant Mycophenolate Mofetil tablets and capsules (of 500mg and 200 mg) in the US.

Mycophenolate Mofetil tablets raked in an estimated $648 million in 2008, while the capsules netted $316 million. The stock opened at Rs 333 and made an intraday high/low of Rs 343/Rs 320.3. The scrip hit a 52-week high of Rs 347 and a low of Rs 222.

 

More From This Section

First Published: May 07 2009 | 12:26 AM IST

Next Story